bs-15963R-BF680 [Conjugated Primary Antibody]
AKT1/3 (Tyr473) Polyclonal Antibody, AbBy Fluor-680 Conjugated
www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: AKT1/3 Tyr473

Modification Site: Tyr473

Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic phosphopeptide derived from human AKT1/3 around the phosphorylation site of Tyr473

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

AKT, also known as protein kinase B (PKB), is a 57 kDa serine/threonine protein kinase. There are three mammalian isoforms of Akt: AKT1 (PKB alpha), AKT2 (PKB beta) and AKT3 (PKB gamma) with AKT2 and AKT3 being approximately 82% identical with the AKT1 isoform. Each isoform has a pleckstrin homology (PH)domain, a kinase domain and a carboxy terminal regulatory domain. AKT was originally cloned from the retrovirus AKT8, and is a key regulator of many signal transduction pathways. Its tight control over cell proliferation and cell viability are manifold; overexpression or inappropriate activation of AKT has been seen in many types of cancer. AKT mediates many of the downstream events of phosphatidylinositol 3 kinase (a lipid kinase activated by growth factors, cytokines and insulin). PI3 kinase recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus.

Conjugation: AbBy Fluor-680

Excitation/ Emission: 679nm/702nm

Size: 100µL

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Dingyang Liet al. Circular RNA CDR1as Exerts Oncogenic Properties Partially through Regulating MicroRNA 641 in Cholangiocarcinoma. Mol Cell Biol. 2020 Jul 14;40(15):e00042-20.Read more>>
  • Liangqi Xie. et al. Effect and mechanism of Jinkui Shenqi Pill on preventing neural tube defects in mice based on network pharmacology. J ETHNOPHARMACOL. 2024 Nov;334:118587Read more>>
VALIDATION IMAGES